Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment
control group:clinical standard antiviral treatment
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years male or female; 2. Body weight 40-100 kg and BMI >= 18kg/m2; 3. Been Confirmed with commom 2019-nCoV pneumonia inpatient; 4. With fever, respiratory tract and other symptoms, imaging shows pneumonia; 5. 2019-nCoV nucleic acid test was positive by pathogenic detection within 72 hours; 6. Have undergone surgical sterilization or take effective contraception during the trial; 7. Written the informed consent.
Exclusion criteria
Exclusion criteria: 1. Infected with other viruses such as HCV, HIV, and syphilis; 2. Used non-steroidal anti-inflammatory drugs within 3 days before enrollment; 3. Have severe liver disease; 4. Those who are known to be allergic to the test drug and its ingredients; 5. Any of the following risk factors: 1) Chronic respiratory diseases such as chronic dual lung disease, acute bronchial respiratory disease; 2) Severe cardiovascular diseases such as congenital hypertension, congestive heart failure, coronary artery disease, except hypertension; 3) Nervous system and neuromuscular diseases, such as cerebral palsy, epilepsy, stroke,Intellectual Disability, muscular dystrophy or spinal cord injury, etc .; 4) Severe blood system diseases such as sickle cell disease; 5) Malignant tumor. 6. Pregnancy or breastfeeding,or positive pregnancy test in a predose examination; 7. Patients who participated in other clinical trials within the last 3 months; 8. Patients who are pregnant or in lactation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Clinical recovery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to improvement of Virus infection symptoms;Length of hospitalization /Healed and discharged;Time to conversion of 2019-nCoV RNA result from RI sample;Rate of preventing mild to moderate patients from shifting to severe patients;Changes in lung inflammation absorption;Time to temperature recovery; | — |
Countries
China
Contacts
Public ContactJun Lin
Zhongnan Hospital of Wuhan University
Outcome results
None listed